Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04233593 · ClinicalTrials.gov registry record · Phase 1
Neuroimmune Response to Lipopolysaccharide
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04233593 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 27 participants.
The verdict
NCT04233593, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
In this study, healthy adult volunteers will undergo two positron emission tomography (PET) scans using the radiotracer \[11C\]PBR28 which binds to the 18kDa translocator protein (TSPO). Approximately 3 hours prior to the second \[11C\]PBR28 PET scan, lipopolysaccharide (LPS; endotoxin) will be administered to evoke a robust neuroimmune response. Subjects will also undergo behavioral and cognitive testing. Vital signs, subjective response, and peripheral cytokine levels will be assayed periodically throughout the experimental session. Specific aims: Quantify the magnitude of neuroimmune response after a classical immune stimulus. Secondary aims: Quantify changes in cognitive function after a classical immune stimulus. Hypothesis: Individuals will exhibit a robust whole-brain neuroimmune response and impaired cognitive function after LPS.
Interventions
- BIOLOGICAL Lipopolysaccharide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-03-25 |
| Est. Completion | 2021-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04233593
The ClinicalTrials.gov registry entry for NCT04233593 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lipopolysaccharide is the first listed.
NCT04233593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04233593 about?
NCT04233593 is a clinical study titled "Neuroimmune Response to Lipopolysaccharide". In this study, healthy adult volunteers will undergo two positron emission tomography (PET) scans using the radiotracer \[11C\]PBR28 which binds to the 18kDa translocator protein (TSPO). Approximately 3 hours prior to the second \[11C\]PBR28 PET scan, lipopolysaccharide (LPS; endotoxin) will be admi...
What is the current status of trial NCT04233593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2014-03-25. Estimated completion is 2021-08-17.
What interventions are being tested in trial NCT04233593?
The interventions under investigation include: Lipopolysaccharide (BIOLOGICAL).
Who is sponsoring clinical trial NCT04233593?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.